Regulatory Strategies for Orphan drug Development in USA–Europe

Ranjini D.M*, Sadiq Basha G, Prabakaran N.

¹Regulatory Executive in Generic Formulation Regulatory Science, Biocon Pharma Limited, 20^th KM,

Hosur Road, Electronic City, Bengaluru, Karnataka 5600100.

²Associate Vice President – Regulatory Science Biocon Pharma Limited, 20^th KM, Hosur Road, Electronic City, Bengaluru, Karnataka 5600100.

³Manager in Regulatory Sciences – Generic Formulations Biocon Pharma Limited, 20^th KM, Hosur Road, Electronic City, Bengaluru, Karnataka 5600100.

*Corresponding Author E-mail: ranjinidm56@gmail.com, gsadiqbasha@gmail.com

ABSTRACT:

Objectives of the present work are as follows:

· To study the current principles of rare diseases & orphan drugs.

· To study the assessment, challenges and regulatory frame work of orphan drugs

· To study the integrated approach for the development and approval of orphan drugs.

· To carry out the study of globalization in orphan drug development strategies in US & EU markets.

Methods: Internet using web page content: The literature was collected using numerous search engines e.g. Science Direct, Google Scholar and many more. Online books also served as a good source of information.

Documents and information’s collected using numerous regulatory websites such as:

a) USFDA: https://www.fda.gov

b) EMA: https://www.ema.europa.eu/en

c) CANADA: https://www.canada.ca/en/health-canada.html

d) TGA: https://www.tga.gov.au/

e) INDIA: http://www.cdsco.com/

Results: US- FDA Approved Orphan Drug ex: Tafenoquine - Treatment of malaria - Krintafel is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria. EU – EMA Approved Orphan Drug ex: Eculizumab, Soliris - Treatment myasthenia gravis. Conclusion: The orphan drug guidelines made via distinct countries have established as promoters in development of orphan drugs. The orphan drug regulation in the US and the EU has been a success in offering remedies to the patients with rare diseases.

KEYWORDS: Regulations of orphan drugs, Regulatory challenges, Regulatory Orphan drug life cycle.

INTRODUCTION:

The definition of orphan and rare sickness is exceptional in one of a kind nations on the bases of the number of sufferers suffering from them. In the USA of America (USA), according to the National Institutes of Health (NIH), 30 million Americans have one of the almost 7,000 sickness that are formally taken into consideration “rare” due to the fact every of these have an effect on much less than 2 hundred, 000 human beings within the United States and affect more than the 2 hundred, 000 humans, however in which healing of fee of improvement and market is very hard. (1) The orphan drug designation relying upon the ratio of the range of sufferers tormented by rare disorder that's 7.5 according to 10,000 individuals within the USA, five per 10,000 people within the EU, 4 according to 10,000 individuals. In the European Union at that time 5000 to 8000 special rare diseases affecting 6% to eight% populace of it. (2) Most rare diseases are genetic; because symptoms do now not appear in advance, they exist at some stage in the individual’s entire existence. (3) The United States was the first country delivered an orphan drug act in 1983, after that range of different nations has observed the program, In Europe Union acts have been made plenty later than the us because its miles organization of 28 international locations and its talents concerning the fitness may be very an awful lot dispersed. (4)

Orphan Drug Definition – According to USA - FDA Regulation

The orphan drug is a medication intended to treat a disease in the United States that affects less than 200,000 individuals. Examples of rare disease: Acromegaly, acute myeloid leukaemia (AML), Ovarian cancer, smallpox, Cushing's disease, Dravet syndrome, Fallopian tube carcinoma, ovarian cancer, cystic fibrosis (CF)(5)

Orphan Drug Designation in USA:

"The Orphan Drug Designation Program" offers orphan status to drugs and biologic identified as those intended to treat, diagnose, or prevent rare disease safely and effectively. A rare disease is a disorder affecting a small proportion of the population. (6) So, called "Orphan drugs" are designed to treat diseases, so rare that marketers are hesitant to produce them under the normal conditions of advertising.

Definition of orphan drugs – In the European Union (EU):

A disease is described as rare if it affects less than 5 out of 10,000 people across the EU. In the European Union, 30 million people are suffering from a rare disease. Examples of rare disease: Ovarian cancer, Huntington’s disease, Systemic sclerosis, Wilson’s disease, Myasthenia gravies, Cystic fibrosis, Glioma. The European Medicine Agency (EMA) plays a central role in promoting the production and approval of rare disease drugs, known in the medical world as "orphan medicines," such as rare disease Mucoviscisis, haemophilia, Phenylketonuria, Marfan syndrome.(7) Most rare diseases are caused by genetic mutations, either inherited (even if the disorder has a late onset in the life of the patient), or caused by a new mutation (de nova) A variety of opportunities in the EU will support the sponsors of approved orphan medicines(8)

Regulation (EC) No 141/2000 (Orphan Regulation)

The European Parliament adopted Regulation (EC) No 141/2000 (Orphan Regulation) on 16 December 1999. This was written on 22 January 2000 in the Official Journal of the European Communities.

The Regulator

· Lays down the EU procedure for designation of orphan medicines

· Defines opportunities for the development and marketing of orphan medicinal

· Products;

· Establishes an Orphan Medicinal Goods Committee (COMP)

Current Regulatory principles of rare disease In United States of America (USA) – Food and Drug Administration (FDA)

The general principles that improve the utility of natural history research in the production of drugs for rare diseases include:

· Conduct a long-term experiment to identify clinically meaningful results and variance during the disease.

· Select data elements based on disease characteristics, including patient-most important signs and symptoms (i.e., disease aspects that are most likely to be life-limiting or life-altering), potential prognostic characteristics, and disease characteristics that can help formulate a sensitive clinical endpoint a sponsor will assess when different manifestations of disease are likely to occur

· Collect data from the results of the clinical evaluation, laboratory tests, imaging, patient quality and feeling studies, 12 and other related sources. Data collection frequency is partly influenced by knowledge of disease characteristics, such as the level of a patient's condition worsening and the occurrence or absence of disease exacerbations.

Current Regulatory principles of rare disease In European Union (EU) – European Medicine Agency (EMA)

PRINCIPLE 1: OMP assessment should take into account all applicable product value elements in an effective multi-dimensional context:

a) Decision-makers should consider the value of OMP from a client, health and wider societal perspective

Principle 2: Pricing and reimbursement decisions should be based on the OMP quality evaluation and adjusted to reflect certain factors beyond the value of the product Principle 3: Those who take P&R decisions on OMPs at national level will take into account all official regulatory and health technology assessments of OMPs carried out at European level.

Regulatory Challenges for Rare Disease Drug Development in USA

· Small populations also restrict the development and replication of research and the use of common inferential statistics.

· Phenotypic variation within a disease, including genetic subsets, adds complexity

· Natural history: experience of the natural history of a disease will inform many important aspects of the trials. It involves preparing the accrual and maintenance of patients for disease-specific challenges to optimize the scale of the premarket protection dataset. Robust information on natural history can also help to differentiate between drugs. (9)

Regulatory Challenges for Rare Disease Drug Development in EU

Challenge 1: Designation of orphan disease and control policy.

Challenge 2: Optimal production of pre-clinical and early drugs.

Challenge 3: Selection of appropriate care outcomes.

Challenge 4: Designing and reviewing criteria for clinical trials and collecting evidence from payers.

Table 1: Regulatory Frame Work Of Orphan Drugs In USA

Title 21: Food and Drugs

Part 316: Orphan drugs

Contents

Subpart A —General Provisions

316.1 – Scope of the medication in the orphan

316.2 – The orphan drug's intent

316.3 – Definitions

316.4 – Address for submission

Subpart B—Professional Recommendations for Orphan Drug Testing

316.10 Content and format of a written advice submission.

316.12 Providing advice in writing.

316.14 Refusal to make recommendations in writing.

Subpart C—Designation of an Orphan Drug

316.20 Material and structure of an orphan-drug classification submission.

316.21 Verification of the status of an orphan drug.

316.22 Global supporter permanent resident member.

316.23 Timing of requests for the classification of orphan drugs; designation of drugs already licensed.

316.25 Refusal of the classification for orphan drugs

316.26 Amendment to the classification of orphaned drugs

316.27 Shift of control of the class of orphan drugs

316.28 Publication of designations for orphan drugs

316.29 Revocation of the status of orphan drugs

316.30 Annual reports of the owner of the class for orphan drugs

Subpart D—Orphan-drug Exclusive Approval

316.31 Exclusive orphan-drug approval range

316.34 Exclusive approval from the FDA

316.36 Insufficient orphan drugs

Subpart E—Open Protocols for Investigations

316.40 Use of a drug known as an orphan

Subpart F—Availability of Information

316.50 Guidance reports

316.52 Transparency of requests and demands for public disclosure of data and information

Technical overview of the proposed regulatory framework for orphan drugs in USA

1. Designation

2. Approval of New Drug Application (NDA)/Biological Licensing (BLA)

Orphan Drug Designation: In general, the Office of Orphan Products Creation may "designate" a drug / biologic for preventing, treating or diagnosing a disease / condition occurring in < 200,000 people in the U.S. (11)

Orphan NDA/ Orphan BLA Approval:

Orphan NDA/ Orphan BLA Marketing Approval of a new drug submitted pursuant to section 505 (b) of the Federal Food, Product and Cosmetic Act OR Marketing Approval of a license for biologic submitted pursuant to section 351 of the Public. (12)

Orphan Drug Designation Request Form:

In 21 CFR 316.20, the nature and structure of an orphan drug classification application are defined. This form (FDA 4035) is intended to assist sponsors in the full and succinct delivery of the required material.

CONCLUSION:

The orphan drug guidelines made via distinct countries have established as promoters in development of orphan drugs. The orphan drug regulation in the US and the EU has been a success in offering remedies to the patients with rare diseases.

ACKNOWLEDGEMENT:

I acknowledge my co-authors for their sincere and dedicated efforts to help me to review and compile the facts and information which helped me to frame this article.

CONFLICTS OF INTEREST:

The authors declare that there are no conflicts of interest.

AUTHORS CONTRIBUTION:

Sadiq Sir Helped me to select the topic, Prabakaran sir helped in framing the title, Shantha Kumar sir helped me to collect the data overall all are helped and support me to completed this work.

REFERNCES:

1. Singh MK, Sharma PK, Sharma N. Orphan Drug Development: A Brief Review. Journal of Pharmacy Research. 2011; 4(8):2645–7. 2.

2. European Medicine Agency [Internet]. Medicines for Rare Diseases: 3–5; 2016 [cited 2016 Apr 13]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ special topics/general/general_content_000034.jsp.

3. Engel PA, Bagal S, Broback M, Boice N. The Need for Stronger Educational Initiatives for Physicians. Journal of Rare Disorder. 2013; 1(2):1–15.

4. Hall AK and Carlson MR. the Current Status of Orphan Drug Development in Europe and the US. International Journal of Rare Disorder Research. 2014; 3(1): 1–7.

5. Orphan Drug Report [Internet]. Welcome to the Evaluate Pharma Orphan Drug Report. [updated 2015 oct 30; cited 2016 Apr 3] Available from: http://www.evaluategroup.Com/public/reports/Evalua tePharma-Orphan-Drug-Report-2015.

6. Jyothi G, Venkatesh M, Kumar PT, Radhadevi N, Gundavaram R and Sharma KK: Orphan Drug Act: History, Perspective and Challenges for Future. Am J PharmTech Res 2012; 2249-3387.

7. Schieppati A, Henter JI, Daina E and Aperia A: Why rare diseases are an important medical and social issue. The Lancet 2008; 371(9629): 2039-41.

8. Haffner ME: Adopting orphan drugs-two dozen years of treating rare diseases. New England Journal of Medicine 2006; 354(5): 445-7.

9. Stakisaitis D, Spokiene I, Juskevicius J, Valuckas KP and Baiardi P: Access to information supporting the availability of medicines for patients suffering from rare diseases looking for possible treatments: the European Service. Medicine (Kaunas, Lithuania) 2007; 43(6): 441-6.

10. Wästfelt M, Fadeel B and Henter JI: A journey of hope: lessons learned from studies on rare diseases and orphan drugs. Journal of Internal Medicine 2006; 260(1): 1-10.

11. FDA. Available from: http://www.fda.gov/downloads/ For Consumers.

Received on 12.05.2020 Modified on 14.07.2020

Research J. Pharm. and Tech. 2021; 14(6):3449-3454.

DOI: 10.52711/0974-360X.2021.00600